In animal models, NU-9 was found to show promise in treating Alzheimer's by reducing toxic protein buildup and brain ...

Schoox, a global leader in frontline workforce learning and skills development, has been selected by the ALS Association to ...

NeuroSense Therapeutics, Ltd. , a leading clinical-stage biotechnology company focused on developing treatments for severe neurodegenerative diseases, today announced promising new findings from its ...

A rare mutation that leads to high CREB3 activity is associated with a reduced risk of developing ALS and slower disease ...

Amylyx (AMLX) announced that the first participant has been dosed in LUMINA, the company’s Phase 1, multinational, randomized, double-blind, ...

The Ohio House Insurance Committee will hear proponent testimony on HB 24, a bill that would expand Medigap coverage to patients under 65, on Tuesday afternoon.

Experimental drug NU-9 - a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) - improves ...

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced enrollment of ...

Experimental drug NU-9 -- a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) -- improves ...

Scientists at Johns Hopkins Medicine say they have discovered how a group of proteins linked to Parkinson's disease and ...

TRE-515, a small molecule inhibitor of deoxycytidine kinase, is being developed for autoimmune diseases and in clinical ...